Avicena Group Inc., of Palo Alto, Calif., received U.S. Patent No. 7,285,573, which covers the use of the company's drug candidates against amyotrophic lateral sclerosis.

CellCyte Genetics Corp., of Kirkland, Wash., received U.S. Patent No. 7,282,222, which covers methods and compositions for delivering and directing stem cells to target organs in the body. That technology, licensed from the Department of Veterans Affairs, is being used to develop stem cell-enabling therapeutic products to improve the delivery and retention of adult stem cells to diseases and other target organs.

CytoGenix Inc., of Houston, received a notice of allowance for a patent on its herpes composition, titled "Treatment of HSV-Related Pathologies Using ssDNA." It covers both composition of matter claims using single-stranded DNA expression vector technologies and methods of treatment using the company's therapeutic compound.